杜尚亭,李玲玉,赵银冰,詹文华

目的：探索纳米粒子粒径对肿瘤细胞内吞及其入胞途径的影响。方法：制备两种不同粒径的纳米粒子，通过细胞内化实验观察两种不同粒径纳米粒子进入肿瘤细胞的差异。利用细胞内吞抑制剂处理人非小细胞肺癌A549细胞，探究纳米粒子粒径对其入胞途径的影响。结果：小粒径纳米粒子入胞速率在初期较大粒径纳米粒子快，入胞量较大粒径纳米粒子多。但至18h时，两种粒径纳米粒子入胞量无显著差异。小粒径纳米粒子主要通过网格蛋白介导的内吞作用入胞，大粒径纳米粒子则通过巨胞饮作用为主、网格蛋白介导的内吞作用为辅的两种方式入胞。结论：不同粒径纳米粒子的入胞速率及入胞途径有明显差异，可为设计粒径可变的纳米药物提供理论依据，以实现更高效的药物靶向递送。

纳米粒子；粒径；细胞内吞机制

[1] Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000 Mar 1;65(1-2):271-84. [2] Germain M, Caputo F, Metcalfe S, Tosi G, Spring K, Åslund AKO, Pottier A, Schiffelers R, Ceccaldi A, Schmid R. Delivering the power of nanomedicine to patients today. J Control Release. 2020 Oct 10;326:164-171. [3] Islam R, Maeda H, Fang J. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors. Expert Opin Drug Deliv. 2022 Feb;19(2):199-212.  [4] Perry JL, Reuter KG, Luft JC, Pecot CV, Zamboni W, DeSimone JM. Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location. Nano Lett. 2017 May 10;17(5):2879-2886.

点击下载PDF